Reyvow is a Oral Tablet in the Human Prescription Drug category. It is labeled and distributed by Eli Lilly And Company. The primary component is Lasmiditan.
Product ID | 0002-4312_1ba572bf-50d9-45aa-b2fb-533be8ea0e38 |
NDC | 0002-4312 |
Product Type | Human Prescription Drug |
Proprietary Name | Reyvow |
Generic Name | Lasmiditan |
Dosage Form | Tablet |
Route of Administration | ORAL |
Marketing Start Date | 2019-10-11 |
Marketing Category | NDA / NDA |
Application Number | NDA211280 |
Labeler Name | Eli Lilly and Company |
Substance Name | LASMIDITAN |
Active Ingredient Strength | 50 mg/1 |
NDC Exclude Flag | N |
Listing Certified Through | 2020-12-31 |
Marketing Start Date | 2020-01-31 |
NDC Exclude Flag | N |
Sample Package? | N |
Marketing Category | NDA |
Application Number | NDA211280 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | EA |
Marketing Start Date | 2020-01-31 |
Ingredient | Strength |
---|---|
LASMIDITAN | 50 mg/1 |
NDC | Brand Name | Generic Name |
---|---|---|
0002-4312 | Reyvow | lasmiditan |
0002-4491 | Reyvow | lasmiditan |
0002-4736 | Reyvow | lasmiditan |
Mark Image Registration | Serial | Company Trademark Application Date |
---|---|
REYVOW 88035791 not registered Live/Pending |
Eli Lilly and Company 2018-07-12 |
REYVOW 87446502 not registered Live/Pending |
Eli Lilly and Company 2017-05-11 |
REYVOW 86926214 not registered Dead/Abandoned |
ELANCO US INC. 2016-03-02 |
REYVOW 85685418 not registered Dead/Abandoned |
Eli Lilly and Company 2012-07-24 |
REYVOW 85042374 not registered Dead/Abandoned |
Eli Lilly and Company 2010-05-19 |
REYVOW 77141452 not registered Dead/Abandoned |
Eli Lilly and Company 2007-03-27 |